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     BSTRACT
This study aimed to evaluate the relationship between the serum concentrations of lidocaine/
monoethylglycinexylidide (MEGX) and their effects on several systems in horses. Five healthy, 
conscious horses received a two-hour placebo intravenous infusion followed by a two-hour lido-
caine infusion (bolus of 1.3 mg/kg over ten minutes followed by a continuous rate infusion of 
0.05 mg/kg/min). Lidocaine and MEGX serum concentrations were sampled every ten to fifteen 
minutes during the experiment, and the presence of muscle fasciculations and loss of balance as 
well as the respiratory, digestive and cardiovascular systems of the five horses were evaluated by 
means of different non-invasive methods. During the lidocaine infusion, the mean (± SD) lidocaine 
and MEGX concentrations were respectively 768.88 ± 93.32ng/ml and 163.08 ± 108.98 ng/ml. The 
infusion of lidocaine significantly influenced the presence of fasciculations, caused a statistically 
but non-clinically significant decrease of systolic and diastolic blood pressures, which were both 
correlated with lidocaine and MEGX serum concentrations, and it increased the duodenal con-
tractions frequency, which was correlated with the serum lidocaine concentration. In this study, 
mild hypotensive and prokinetic effects of short-term lidocaine infusion were observed. 
SAMENVATTING
Deze studie had als doel de relatie te bepalen tussen de serumconcentraties van lidocaïne/mono-
ethylglycinexylidide (MEGX) en hun effect op de verschillende lichamelijke stelsels bij het paard. Vijf 
gezonde paarden bij bewustzijn kregen een twee uur durende placebo-intraveneuze infusie gevolgd door 
een twee uur durende lidocaïne-infusie (bolus van 1,3 mg/kg in tien minuten gevolgd door een constante 
infusie van 0,05 mg/kg/min). De lidocaïne- en MEGX-serumconcentraties werden om de tien à vijftien 
minuten gemeten. Het evenwichtsverlies, de spiertrillingen, het ademhalings-, spijsverterings- en car-
diovasculaire stelsel werden beoordeeld met behulp van verschillende niet-invasieve methoden. Tijdens 
de toediening van de lidocaïne-infusie was de gemiddelde (± standaarddeviatie) lidocaïne- en MEGX-
concentratie respectievelijk 768,88 ± 93,32 ng/ml en 163,08 ± 108,98 ng/ml. De toediening van een lido- 
caïne-infusie beïnvloedde significant de aanwezigheid van trillen. Ook veroorzaakte ze een statistisch 
maar niet-klinisch significante afname van de systolische en diastolische bloeddruk, die beide correleer-
den met de lidocaïne- en MEGX-serumconcentratie. Verder verhoogde ze eveneens de duodenale con-
tractiefrequentie, die correleerde met de serumlidocaïne-concentratie. In de voorliggende studie werden 
milde hypotensieve en prokinetische kortetermijneffecten van een lidocaïne-infusie waargenomen.
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INTRODUCTION
Intravenous lidocaine is frequently used in horses 
in different medical conditions. In cardiac pathologies, 
it is used as an antiarrhythmic drug to treat ventricular 
tachycardia (McGuirk and Muir, 1985). It has analge-
sic properties (Murrell et al., 2005; Robertson et al., 
2005) and its systemic administration decreases the 
anesthetic requirements of inhalant agents (Doherty 
and Frazier, 1998). It is also commonly used in horses 
with digestive problems, to treat and prevent ileus 
and gastrointestinal pain in the postoperative period 
or in horses with small intestine inflammatory disease 
(Brianceau et al., 2002; Malone et al., 2006; Torfs et 
al., 2009), and to improve mucosal repair after ische- 
mic intestinal injury (Cook et al., 2008). Lidocaine 
treatment has been associated with enhanced short-
term survival of horses after colic surgery (Torfs et 
al., 2009). 
The dosage of intravenous lidocaine commonly 
used in horses is a bolus of 1.3mg/kg (usually admin-
istered over 5-15 minutes) followed by a continuous 
rate infusion (CRI) of 0.05mg/kg/minute, as recom-
mended by Malone et al., (1998). 
When administered intravenously, lidocaine has 
been associated with several side effects, mainly af-
fecting the central nervous, musculoskeletal and car-
diovascular systems. 
Eye blinking, anxiety, mild sedation, muscle fas-
ciculation, ataxia and collapse are the most commonly 
reported signs of toxicity in clinical use in horses 
(Brianceau et al., 2002; Malone et al., 2006; Meyer 
et al., 2001). 
Lidocaine is metabolized by the liver and is trans-
formed by the cytochrome P450 system in mono- 
ethylglycinexylidide (MEGX), which is further meta- 
bolized to glycinexylidide (GX) and 4-hydroxy-2,6-
xylidine (Oellerich et al., 1987). The adverse reac-
tions related to the use of continuous intravenous 
lidocaine have been attributed in some cases to the 
accumulation of lidocaine or its principal metabolites 
MEGX and GX (Strong et al., 1973) and are usually 
associated with a too high infusion rate leading to a 
lidocaine serum concentration higher than the target 
therapeutic range of 1–2 mg/dL (Meyer et al., 2001; 
Brianceau et al., 2002; Malone et al., 2006). Clini-
cally, lidocaine side effects usually respond rapidly to 
discontinuation or slowing of the infusion rate. There 
is no evidence of structural damage to nerve fibers or 
cells after lidocaine toxicity in other species (Richie 
and Greene, 1990).
The pharmacokinetics of lidocaine and its metabo-
lites have been described in healthy, conscious horses 
(Dickey et al., 2008) and in healthy (Milligan et al., 
2006) or colic horses (Navas de Solís and McKenzie 
III, 2007) after laparotomy, but the relationship be-
tween lidocaine or its metabolites concentrations and 
their pharmacologic effects has not been described in 
depth. Several studies have been conducted in con-
scious and healthy horses in order to evaluate the ef-
fect of a specific dosage of intravenous lidocaine on 
somatic and visceral nociception (Robertson et al., 
2005), on cardiac electrical activity and blood pres-
sure (Meyer et al., 2001) or on gastrointestinal moti-
lity (Milligan et al., 2007; Rusiecki et al., 2008).  
The aim of the present study was to evaluate the 
effects of an infusion of lidocaine and to determine 
the correlations between the serum concentrations of 
lidocaine/MEGX and their effects on the behavior and 
the respiratory, cardiovascular and gastrointestinal 
systems of healthy horses during an infusion of lido-
caine at the dosage commonly used in clinical cases.
MATERIAL AND METHODS
This study was approved by the Ethical Commit-
tee of the University of Liège (number 385). 
Animals 
Five warmblood horses (four mares and one geld-
ing) were used in the study. Their weight ranged from 
418 to 497 kg (mean ± SD: 493 ± 92,6 kg) and their 
age ranged from 11 to 22 years (mean ± SD: 16,4 ± 
5,8 years). All horses were clinically healthy based on 
the history and on an in-depth clinical examination. 
The horses were kept in stall with straw bedding. 
They had access to hay and water ad libitum excepted 
the twelve hours preceding the protocol, when they 
were fasted using a muzzle without restriction of wa-
ter. The day before the protocol, the abdominal region 
of the animals was clipped. During the protocol, the 
horses had no access to water and food.
Study design
Each horse was evaluated during a two-hour intra-
venous infusion of a placebo (NaCl 0.9%, Baxter – 
Viaflo, Belgium) followed by a two-hour intravenous 
infusion of lidocaine (Xylocaine 2%, Astra Zeneca, 
Belgium).
Protocol 
The experiment was carried out in the morning 
for every horse. Within one hour before starting the 
protocol, a 14-gauge polytetrafluoroethylene catheter 
(Catheter 14G Intraflon 2, Vygon, France) was placed 
aseptically into both the left and right jugular veins. 
The skin at the area of the catheter placement was not 
anesthetized with lidocaine in order to avoid interfer-
ence with the subsequent measurements of lidocaine 
and MEGX. The catheter in the left jugular vein was 
used for administration of the infusions, and the cathe- 
ter in the right jugular vein was used to collect the 
blood samplings. 
The infusion of lidocaine was performed at the 
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usual clinical dosage and consisted of a single intra-
venous bolus of 1.3 mg/kg of lidocaine administered 
over 10 minutes followed by a CRI of 0.05 mg/kg/
min during 110 minutes (Malone et al., 1998). One 
volume of commercial lidocaine 2%² (20 mg/ml) was 
added to four volumes of saline in order to obtain a 
concentration of 4 mg/ml solution of lidocaine. The 
infusion of placebo consisted of the administration of 
NaCl 0.9% at the same rate as the lidocaine infusion. 
The rate of administration of both fluids was con-
trolled by use of an intravenous fluid administration 
pump (Flo-Gard 6200, Baxter, Belgium).
Timing of the investigations
The following times (Tminutes) were defined: 
T0 (prior to lidocaine or placebo administration) and 
T10, T15, T30, T45, T60, T75, T90, T105 and T120 
(minutes following the beginning of the lidocaine or 
placebo administration). The continuously evaluated 
parameters were classified in periods finishing at the 
corresponding T time (for example: T30 corresponds 
to the period beginning just after T15 and ending at 
T30).
Behavioral evaluation
The presence of muscle fasciculations and loss of 
balance was recorded throughout the experiment and 
was scored as 0 (absence) or 1 (presence) for the cor-
responding time period.  
Respiratory evaluation
The respiratory rate was obtained by feeling the 
expiratory airflow with a hand placed near the exter-
nal nare and watching the horse’s nostril movements 
during one minute at each time point (McGorum and 
Dixon, 2007). 
Cardiovascular evaluation
Heart rate and electrocardiographic (ECG) analysis
For each horse, an ECG was recorded continu-
ously from 15 minutes preceding the start of the infu-
sion (lidocaine or placebo) until the end of the infu-
sion by using a Holter system (System Holter Vista, 
Novacor, France). Data were retrospectively blindly 
analyzed after their transfer on a computer. The pres-
ence of arrhythmias was evaluated by visual inspec-
tion of the ECG tracings and controlled by an ECG 
analyzer program (HolterSoft Ultima 2.5.5, Novacor 
2001-2009, France). The heart rate was calculated by 
visual inspection of the ECG tracing (number of QRS 
complexes) during the last minute of each time pe-
riod. The type and the frequency of the possible car-
diac arrhythmias were recorded and attributed to the 
corresponding T time. 
Systemic arterial blood pressure
Systolic and diastolic systemic arterial blood 
pressures were collected using a non-invasive oscil-
lometric system (Digital blood pressure monitor KH 
8088, Kompernass, Germany). The inflatable cuff for 
the blood pressure measurement had a length of 25 
cm and a width of 5.5 cm. It was positioned at the 
base of the tail and centered over the coccygeal artery. 
For each time point, the systolic and diastolic arterial 
pressures were obtained by calculating the mean of 
three consecutive measurements (Parry et al., 1980). 
Gastrointestinal evaluation
Gut sounds
Gut sounds were evaluated by auscultation of the 
left flank during one minute for each time point and 
recorded as the number of peristaltic sounds heard 
over one minute.
 
Duodenal ultrasonography
The duodenum was examined by transabdominal 
ultrasonography (Aloka SSD 900, Aloka Holding 
Europe AG, Switzerland) in the middle third (dorso-
ventrally) of the abdomen between the fourteenth 
and seventeenth right intercostal spaces just ventral 
to the right kidney and dorsal or dorsolateral to the 
cecal base, as described by Kirberger et al. (1995). 
Appropriate contact between the ultrasonographic 
probe (Convex transducer UST 990-3.5 MHz, Aloka 
Holding Europe AG, Switzerland) and the skin was 
provided by the previous clipping of the hair and a 
contact gel applied directly on the skin at the time 
of the examination. The ultrasonographic images of 
the duodenum during the last three minutes of each 
T period were recorded on a videotape for later blind 
evaluation. Subsequently, the recording was used to 
obtain the frequency of the duodenal contractions and 
the duodenal wall thickness, which was measured 
when the intestine was fully open. The frequency of 
the contractions of the duodenum was calculated us-
ing the entire recording for each T period. The value of 
the duodenal wall thickness was obtained by the mean 
of three measurements, which were taken from the 
hyperechoic outer serosal surface to the inner hyper- 
echoic mucosal surface (Figure 1).
Blood sampling and laboratory methods
At each T time, a 5-ml blood sample was collected 
from the right jugular catheter and placed into a plain 
vacuum tube (Vacuette 9 ml Z Serum Clot activator, 
Greiner Bio-One GmbH, Austria). The blood sample 
was allowed to clot before being centrifuged (Centri-
fuge EBA 200S, Hettich, Germany) at 4000 rpm for 
ten minutes at room temperature. The serum was then 
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frozen within one hour after collection (Dasgupta et 
al., 1996) and was kept at –20°C until analyzed.
The concentrations of lidocaine and MEGX were 
determined by a validated high-performance liquid 
chromatography combined with electrospray ioniza-
tion tandem mass spectrometry as described by Maes 
et al. (2007).
Statistical analysis
Variables are given as the mean ± standard devia-
tion (SD). A chi-square test was used to evaluate the 
effect of treatment on behavior (presence or absence 
of muscle fasciculation and loss of balance).
A mixed linear model was applied to the other para- 
meters after a Boxcox transformation for the data that 
did not follow a Gauss distribution. The mixed model 
included the fixed effects of treatment and time within 
treatment and the random effect of horse. With this 
model, a sample size of five horses should be enough 
to detect significant differences between treatment, 
with a power of 80% and an alpha error of 5%.  
Pearson correlations were computed between all 
parameters (with the exception of behavior) and the 
concentrations of lidocaine and MEGX obtained dur-
ing the lidocaine infusion. The significance level was 
set at p < 0.05. All computations were done on SAS 
9.1 (SAS/STAT 9.1 User’s Guide. Cary, NC: SAS In-
stitute Inc. 2004).
RESULTS
Serum concentrations of lidocaine and MEGX
No lidocaine nor MEGX were detected in the se-
rum samples collected during the infusion of the pla-
cebo. 
The concentrations of lidocaine and MEGX ob-
tained from blood samples collected during the infu-
sion of lidocaine are displayed in Figures 2, 3 and 4A. 
In all horses, after a rapid increase during the in-
fusion of the bolus, the concentrations of lidocaine 
reached a steady state.  In all horses, the lidocaine con- 
centrations during the steady state ranged between 
601ng/ml and 992 ng/ml. The mean lidocaine con-
centration during the lidocaine infusion was 768.88 
± 93.32ng/ml. 
The evolution of the MEGX concentrations pre-
sented a larger inter-horse variability with almost a 
steady state reached after T30 in one horse (horse 5), 
a continuous but slow increase in two horses (horses 
1 and 4) and a quick and continuous increase in two 
horses (horses 2 and 3). The mean MEGX concen-
tration during the lidocaine infusion was 163.08 ± 
108.98 ng/ml. 
Figure 1. Landmarks used to measure the duodenal 
wall thickness: from the hyperechoic outer serosal sur-
face to the inner hyperechoic mucosal surface.
Figure 2. Serum concentrations of lidocaine (ng/ml) 
during an intravenous infusion of lidocaine (1.3mg/kg 
over ten minutes followed by a continuous rate infusion 
of 0.05 mg/kg/min during 110 minutes) in five healthy, 
conscious horses. 
Figure 3. Serum concentrations of MEGX (ng/ml) dur-
ing an intravenous infusion of lidocaine (1.3mg/kg over 
ten minutes followed by a continuous rate infusion of 
0.05 mg/kg/min during 110 minutes) in five healthy, 
conscious horses.
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Effects of the infusion of lidocaine and their corre-
lations with the lidocaine/ MEGX concentrations
Behavioral effects
There was a significant effect of treatment (placebo 
or lidocaine infusion) on the presence of muscle fas-
ciculations (p ≤ 0.001). None of the horses presented 
muscle fasciculations during the infusion of the pla-
cebo, while four of the five horses presented muscle 
fasciculations during the administration of lidocaine. 
In all of those four horses, the muscle fasciculations 
were noted at T10 and T15, corresponding to the 
loading dose injection (bolus) and the beginning of 
the CRI. However, some of the horses also presented 
muscle fasciculations at other T times. None of the 
horses showed loss of balance during both infusions. 
Respiratory effects
The mean respiratory rate was significantly lower 
(p ≤ 0.01) during the lidocaine infusion (8.2 ± 2.5 
bpm) than during the placebo infusion (9.0 ± 2.7 
bpm), and the decrease in respiratory rate was signifi-
cantly correlated with the serum MEGX concentra-
tion but not with the lidocaine concentration (Table 1 
and Figures 4A and 4B). 
Cardiovascular effects
There was no effect of treatment on the heart rate 
(40 ± 8 bpm during the placebo infusion and 38 ± 
5 bpm during the lidocaine infusion). There was no 
correlation between the heart rate and the lidocaine/ 
MEGX concentrations (Figures 4A and B). 
The complete examination of the ECG trace be-
fore and during the administration of both the placebo 
and the lidocaine revealed the absence of cardiac ar-
rhythmias. 
Despite the absence of influence of treatment on 
the heart rate, the mean systolic blood pressure was 
significantly lower (p ≤ 0.001) during the lidocaine 
infusion (128.2 ±17.5 mmHg) than during the pla-
cebo infusion (144.3 ± 23.4 mmHg). Similarly, the 
mean diastolic blood pressure was significantly lower 
Table 1. Pearson correlation coefficients (r) of the analysis between the tested parameters and the concentrations of 
lidocaine and MEGX.
  
  Lidocaine MEGX
Tested parameter  concentration concentration
Respiratory rate r -0.1838 -0.2586 (*)
Heart rate r -0.1123 -0.1415
Systolic blood pressure r -0.3578 (**) -0.3750 (**)
Diastolic blood pressure r -0.2537 (*) -0.2419 (*)
Frequency of the gastrointestinal sounds r -0.2281 (*) -0.0094
Frequency of the duodenal contractions r -0.2574 (*) -0.0461
Duodenal wall thickness r -0.0145 -0.0444
* : p < 0.05 ; ** : p < 0.001
Figure 4A. Evolution of the mean (+ SD) serum concen-
trations of lidocaine (ng/ml) and MEGX (ng/ml) as a 
function of time during an experimental intravenous in-
fusion of lidocaine (1.3mg/kg over ten minutes followed 
by a continuous rate infusion of 0.05 mg/kg/min during 
110 minutes) in five healthy, conscious horses. 
A
Figure 4B. Evolution of the mean (+ SD) heart rate (HR) 
and respiratory rate (RR) as a function of time in five 
horses receiving either a lidocaine infusion at 1.3mg/kg 
over ten minutes followed by a continuous rate infusion 
of 0.05 mg/kg/min during 110 minutes (lidocaine) or a 
saline infusion at the same rate (control) during 120 
minutes. Bpm = beats/minute. 
B
(p ≤ 0.05) during the lidocaine infusion (89.6 ±15.9 
mmHg) than during the placebo infusion (96.4 ± 18.5 
mmHg).
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Both systolic and diastolic arterial blood pres-
sures significantly correlated with both lidocaine and 
MEGX serum concentrations (Table 1 and Figures 4A 
and 4C). 
Gastrointestinal effects
The mean frequency of the gut sounds heard in the 
left flank was not significantly different during the 
treatment with lidocaine (4.9 ± 2.5 borborygmi heard/ 
min) and during the administration of the placebo (4.1 
± 2.2 borborygmi heard/ min). However, there was a 
significant correlation between this clinical parameter 
and the serum concentration of lidocaine but not of 
MEGX (Table 1 and Figures 4A and 4D). 
The duodenum contractions frequency evaluated 
by ultrasonography was significantly increased (p ≤ 
0.01) by the treatment with lidocaine (2.6 ± 0.7 con-
tractions/min) compared with the placebo (2.3 ± 0.7 
contractions/ min). Moreover, this parameter signifi-
cantly correlated with the serum lidocaine concentra-
tion, but not with the MEGX concentration (Table 1 
and Figures 4A and 4E). The lidocaine treatment did 
not significantly influence the duodenal wall thick-
ness. During the placebo infusion, the mean duodenal 
wall thickness was 0.41 ± 0.05 cm and it was 0.41 ± 
0.04 cm during the lidocaine infusion. For this para-
meter, there were no correlations with the serum lido-
caine and MEGX concentrations (Table 1 and Figures 
4A and 4E). 
DISCUSSION
While the effects of lidocaine have already been 
extensively evaluated in horses, the present study has 
the particular purpose of studying the relationship be-
tween respiratory, digestive and cardiovascular effects 
and the serum concentration of lidocaine and its prin-
cipal metabolite, MEGX. Among the benefits of the 
present study, the use of conscious, fasted horses was 
chosen to mimic the clinical conditions of the early 
postoperative period of colic horses, as clearance of 
lidocaine has been shown to decrease when horses are 
fasted (Engelking et al., 1987). The study involved 
healthy horses in order to evaluate the specific effects 
of lidocaine/MEGX without a possible modification 
of the metabolism of lidocaine (and therefore its con-
centrations) by a pathological process or without the 
possible interference with other treatments. Ultraso-
nography, the recording of the ECG via a Holter sys-
tem and the measurement of the blood pressure by an 
oscillometric system to evaluate the effects of treat-
ment, were chosen because these methods proved to 
be reliable in a clinical setting, and because they are 
non-invasive, which allows reducing the experiment-
induced stress and respect animal welfare. Moreover, 
the study design (saline infusion followed by lido-
Figure 4C. Evolution of the mean (+ SD) systolic and dia- 
stolic systemic arterial pressure (SAP) as a function of 
time in five horses receiving either a lidocaine infusion 
at 1.3mg/kg over ten minutes followed by a continuous 
rate infusion of 0.05 mg/kg/min during 110 minutes (li-
docaine) or a saline infusion at the same rate (control) 
during 120 minutes.
Figure 4D. Evolution of the mean (+ SD) frequency 
of gut sounds heard in the left flank as a function of 
time in five horses receiving either a lidocaine infusion 
at 1.3mg/kg over ten minutes followed by a continuous 
rate infusion of 0.05 mg/kg/min during 110 minutes (li-
docaine) or a saline infusion at the same rate (control) 
during 120 minutes.
Figure 4E. Evolution of the mean (+ SD) duodenal con-
traction (DC) and duodenal wall thickness (DWT) as a 
function of time in five horses receiving either a lido-
caine infusion at 1.3mg/kg over ten minutes followed by 
a continuous rate infusion of 0.05 mg/kg/min during 110 
minutes (lidocaine) or a saline infusion at the same rate 
(control) during 120 minutes.
C
D
E
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caine infusion within the same day rather than given 
separately), was chosen to respect animal welfare.
Nevertheless, the present study also has several 
limitations. The study was not totally blinded and the 
placebo was first administered in all cases in order to 
avoid meddling of the effects of the residual serum 
lidocaine concentrations with those of the placebo 
during the placebo-administration period. However, 
the principal investigator was not aware of which 
treatment (lidocaine versus placebo) was adminis-
tered during the experimental procedure or reading 
of the recorded parameters. The number of horses in 
this study was small (n=5) but this sample size was 
confirmed to be sufficient by a power calculation. An-
other important limitation was the fact that the infu-
sions were performed in a limited period of time (two 
hours), which can be considered short as in clinical 
use, the duration of lidocaine infusion is often longer 
and some effects of lidocaine or its metabolites might 
have appeared later. Indeed, contrarily to the lido-
caine concentrations that reached a steady state after 
the bolus administration, the concentration of MEGX 
continued to increase in some horses in the study, and 
not all of them appeared to reach a steady state after 
two hours of treatment. However, Dickey et al. (2008) 
revealed that the MEGX concentrations reached a 
steady state of approximately 450 ng/ml (higher than 
all, except one, of the MEGX values in the present 
study) after 3-6 hours of CRI and did not accumulate 
over time, while GX, another potentially toxic active 
lidocaine metabolite, accumulates significantly up to 
48 hours. Therefore, the lack of dosage of GX in the 
present study is also a limitation.  
 Based on the study by Malone et al. (1998), the 
administration of 1.3mg/kg of lidocaine as a bolus 
followed by a CRI of 0.05mg/kg/min permits to 
reach the therapeutic level of 980 ng/ml (range 1000-
2000ng/ml). However, in the present study, concentra-
tions of lidocaine reached the target therapeutic level 
of 980 ng/ml in only one horse at the end of the bolus 
(T10) and at the end of the CRI (T120). During the 
CRI of lidocaine, the other serum lidocaine concen-
trations ranged from 600 ng/ml to 977 ng/ml (which 
can be considered as slightly below to below the target 
level); the toxic level of lidocaine (1850 - 4530 ng/ml 
(Meyer et al., 2001)) was never reached. Nevertheless, 
the serum pharmacokinetics of lidocaine and MEGX 
in the present study were close to those described by 
Robertson et al. (2005). In studies where lidocaine 
was administered to pathological or healthy horses as 
an infusion at the same rate as in the present study, the 
therapeutic level was sometimes reached (Brianceau 
et al., 2002; Dickey et al., 2008), and sometimes not 
(Robertson et al., 2005; Navas de Solís and McKenzie 
III, 2007; Cook et al., 2008). Several hypotheses may 
be made to explain the failure to reach the 980 ng/ml 
in the majority of cases in the present study. As already 
mentioned, the experiments of the present study were 
performed over a relatively short period of time and 
included only healthy horses. Pathological cases such 
as horses suffering from postoperative ileus may suf-
fer from endotoxic shock, associated with a decrease 
in cardiac output and/ or hepatic dysfunction, condi-
tions that have been shown to lead to a decrease of 
systemic lidocaine turnover (Engelking et al., 1987; 
McKindley et al., 2002). Furthermore, pathologic 
horses are susceptible to receiving concurrent drugs 
that are known to potentially affect the lidocaine me-
tabolism or clearance, such as erythromycin (Orlando 
et al., 2003), which can also be used as a gastrointesti-
nal prokinetic drug, fluoroquinolones (Isohanni et al., 
2005) and cimetidine (Feely et al., 1982). Finally, the 
serum concentration of 980 ng/ml of lidocaine may 
not be necessary to produce a therapeutic or toxic ef-
fect as lidocaine is protein bound (53.06 ± 10.28% of 
in vitro protein binding of lidocaine in equine plasma 
at 2 µg/ml) and only the unbound drug is available 
to produce a pharmacological effect (Milligan et al., 
2006). In vitro, flunixin and ceftiofur have resulted 
in increased unbound lidocaine concentrations (Mil-
ligan et al., 2006). Low serum protein concentration 
at the time of lidocaine infusion can also increase the 
drug available to produce an effect despite no change 
in total concentration. Unfortunately, the serum pro-
tein concentrations were not evaluated in the present 
study, but they were assumed to be within the normal 
range as all studied horses were healthy.  
In a study conducted in healthy horses by Meyer 
et al. (2001), lidocaine intoxication was defined as the 
development of skeletal muscle tremor. In the present 
study, muscle fasciculations were observed in four of 
the five studied horses at the beginning of the lido-
caine administration (during the loading dose and the 
beginning of the CRI); these muscle fasciculations 
disappeared in all cases before the end of the CRI 
without slowing the rate of infusion. The appearance 
of toxic signs, despite the low serum concentrations 
of lidocaine and MEGX, may possibly be caused by 
a high unbound lidocaine concentration. The timing 
of appearance of this mild toxic effect of lidocaine 
may also be explained by the fact that the severity of 
neurological symptoms caused by lidocaine are prob-
ably more dependent on the speed of exposure of 
brain cells to local anesthetics rather than on a defined 
blood concentration (Scott 1986; Haasio et al., 1988; 
Skarda, 1991). 
The cardiovascular system of horses is consider-
ably more resistant than the central nervous system 
to the toxic effects of intravenous lidocaine (Meyer et 
al., 2001; Wagman et al., 1967). Therefore, when lido-
caine is used at the usual clinical dosage, few cardio-
vascular side effects have been reported. In the pres-
ent study, lidocaine infusion did not modify the heart 
rate of the five healthy, awake horses, as was found 
in other studies conducted at the same dosage in con-
scious, healthy (Rusiecki et al., 2008) or colic horses 
(Malone et al., 2006), in healthy horses overdosed in 
lidocaine until the onset of the first signs of intoxica-
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tion (muscle fasciculations) (Meyer et al., 2001) and 
in horses anesthetized for castration (Murrell et al., 
2005) or for colic surgery (Feary et al., 2006). Admin-
istered at the dose of 1.3 mg/kg in bolus followed by 
a CRI of 0.05 mg/kg/min, lidocaine is not known to 
produce cardiac arrhythmias, as was the case in the 
present study. However, Mullen et al. (2009) reported 
a case of supraventricular tachycardia and auriculo-
ventricular blocks in a horse with colic treated with 
lidocaine infusion at the usual dosage. The authors of 
this report suggested that the arrhythmias were caused 
by the abdominal distention, which is hypothesized to 
cause vagal stimulation in horses (Abutarbush, 2006) 
in combination with a mechanism (Lieberman et al., 
1968), by which lidocaine increases sinoatrial nodal 
discharge rate. The low doses of xylazine and butor-
phanol administered to this horse one hour before 
starting the lidocaine treatment may also have con-
tributed to the development of the arrhythmias (Mul-
len et al., 2009). Based on their observations, Mullen 
et al. (2009) advised that horses that develop skeletal 
muscle fasciculations during treatment with lidocaine 
should be evaluated for cardiac arrhythmias. If the ar-
rhythmias appear, lidocaine administration should be 
slowed or discontinued. However, in a study, in which 
horses were administered an overdose of intravenous 
lidocaine until the onset of clinical signs of intoxica-
tion (muscle fasciculations), no arrhythmias were ob-
served (Meyer et al., 2001). 
In the aforementioned study by Meyer et al. (2001), 
lidocaine did not significantly modify the mean sys-
tolic and diastolic blood pressures. The mean arterial 
blood pressure was neither modified by the adminis-
tration of lidocaine in a protocol of experimentally 
induced endotoxemia in conscious horses (Peiro et 
al., 2010), nor in horses anesthetized for colic surgery 
(Feary et al., 2006). On the contrary, lidocaine and 
MEGX were associated with a significant decrease of 
the systolic and diastolic blood pressures in the pres-
ent study. Nonetheless, the blood pressure values ob-
tained here were all within or slightly above the pub-
lished ranges of normal values taken non-invasively 
at the coccygeal artery of resting horses (Parry et 
al., 1984). Therefore, although statistically signifi-
cant, this hypotensive effect could be considered as 
clinically irrelevant. To the authors’ knowledge, a 
severe lidocaine-induced hypotension in equids has 
only been described when a large and rapid lidocaine 
overdose was systemically delivered, i.e. 5 mg/kg ad-
ministered intravenously over five minutes to ponies 
anesthetized with halothane (Doherty and Frazier, 
1998). This hypotensive effect may be caused by the 
vasoactive (vasodilator) properties of the lidocaine 
(Demaria et al., 2003).
In in vitro studies, it has been demonstrated that 
lidocaine enhances the contractility of intestinal 
smooth muscle (Nieto et al., 2000; Guschlbauer et al., 
2010; Tappenbeck et al., 2013). On the other hand, 
lidocaine has been shown to decrease the duration of 
(postope-rative) ileus in clinical studies on horses suf-
fering from colic (Malone et al., 2006; Torfs et al., 
2009). However, using the usual lidocaine dosage 
of the aforementioned studies, other authors failed 
to demonstrate a prokinetic effect of lidocaine on 
clinically normal horses by the placement of bipo-
lar electrodes on the proximal jejunum to record the 
migrating myoelectrical complexes (Milligan et al., 
2007) or by the administration of barium-filled mi-
crospheres by nasogastric intubation (Rusiecki et al., 
2008). Therefore, the beneficial effects of lidocaine 
on intestinal motility in horses suffering from ileus 
were supposed to be more attributable to its anti-in-
flammatory effects than to its prokinetic or analgesic 
effects (Cook and Blikslager, 2008). Indeed, the vis-
ceral analgesia provided by systemically administered 
lidocaine has been shown to be ineffective in studies 
on horses (Robertson et al., 2005; Cook et al., 2008). 
Surprisingly, in the present study, a positive correla-
tion value of the coefficient was found between the 
concentrations of lidocaine and the frequencies of the 
borborygmi auscultated in the left flank and of the 
duodenal contractions evaluated by ultrasonography. 
Even if the correlation with the borborygmi can be 
somewhat debatable as the auscultation of the intes-
tinal gut sounds in only one place in the left flank is 
not very accurate nor sensitive, the result on the duo-
denal contractions cannot be so controversial. It can 
be assumed to be related to the initial peak of contrac-
tions observed after the administration of the bolus. 
The evaluation of the duodenum in the present study 
was chosen for two reasons: First, it is a part of the 
intestine that suffers frequently from distention when 
horses suffer from ileus, and thus it is an interesting 
zone for evaluating the effect of lidocaine. Secondly, 
the ultrasonography of this region allows a quantifi-
able and objective evaluation of the intestinal motility 
as the same part of the intestine, the duodenum, can 
be almost constantly visualized using the same ultra-
sonographic window (Kirberger et al., 1995). The re-
sults are in contrast with the results of a study by Bri-
anceau et al. (2002), in which no effect of lidocaine 
on the duodenal contractions frequency was found. 
However, that study was performed in horses that un-
derwent colic surgery, using a scoring system for the 
evaluation of the duodenum motility attributing the 
score 0 every time there was 0 to 3 duodenal contrac-
tions per minute rather than taking into account the 
number of contractions per minute. However, fasted 
horses have less contractions of the duodenum than 
fed horses (Kirberger et al., 1995). Therefore, this 
scoring system may have masked a mild effect. Al-
though the horses of the present study were fasted, 
the number of duodenal contractions during both the 
placebo and the lidocaine infusions were closer to the 
number of duodenal contractions of fed horses than 
to those of the starved horses in the Kirberger study 
(1995). In the present study, the horses were subjected 
to a twelve-hour fasting period, whereas the horses 
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in the Kirberger study (1995) were fasted during 36 
hours. This suggests that twelve hours of fasting is 
probably too short to reduce the intestinal motility of 
the duodenum. It would be interesting to verify if the 
prokinetic effect of lidocaine would still be observed 
after a longer fasting period. 
In conclusion, in this study, it was shown that lido-
caine administered intravenously at the usual clinical 
dosage induces a clinically non-significant systemic 
arterial hypotension, which is correlated with both se-
rum lidocaine and MEGX concentrations, and stimu-
lates the frequency of duodenal contractions, which is 
correlated to the serum lidocaine concentration. Fur-
ther studies using longer infusion durations and/ or 
longer fasting periods in a larger population of horses 
are warranted to confirm these results. 
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